Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25144303 | 0.85 | HTT (0.33) | TSHR | |
| SCHEMBL30465794 | 0.77 | CYP2A6 (0.34) | CA2 | |
| SCHEMBL2029268 | 0.77 | CYP2A6 (0.34) | CA2 | |
| SCHEMBL8840123 | 0.77 | NOS3 (0.32) | CYP3A4TSHRCYP2C19CA2 | |
| SCHEMBL993753 | 0.77 | CCR1 (0.38) | CYP3A4TSHRCYP2C19 | |
| SCHEMBL22543805 | 0.76 | ALOX5AP (0.33) | — | |
| SCHEMBL27592575 | 0.76 | NOS2 (0.40) | — | |
| Ammonia Solution, Strong SCHEMBL28822904 | 0.76 | CYP2A6 (0.33) | — | |
| SCHEMBL25144093 | 0.76 | ATR (0.30) | — | |
| SCHEMBL9772791 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132310-A1 | HIGH STRENGTH URETHANE ACRYLATE HYBRID STRUCTURE ADHESIVES | ARKEMA FRANCE (FR) | 2026-05-14 | — | — | US | claimed |
| US-10844254-B2 | Urethane acrylate hybrid structure adhesives | HERCULES LLC (US) | 2020-11-24 | — | — | US | claimed |
| EP-3676303-A1 | URETHANE ACRYLATE HYBRID STRUCTURE ADHESIVES | Hercules LLC (US) | 2020-07-08 | — | — | EP | claimed |
| US-10246481-B2 | Bile acid derivatives and methods for synthesis and use | CITY OF HOPE (US) | 2019-04-02 | — | — | US | claimed |
| WO-2019046200-A1 | URETHANE ACRYLATE HYBRID STRUCTURE ADHESIVES | HERCULES LLC (US) | 2019-03-07 | — | — | WO | claimed |
| US-20180319836-A1 | BILE ACID DERIVATIVES AND METHODS FOR SYNTHESIS AND USE | HOPE CITY (US) | 2018-11-08 | — | — | US | claimed |
| US-20170233431-A1 | BILE ACID DERIVATIVES AND METHODS FOR SYNTHESIS AND USE | HOPE CITY (US) | 2017-08-17 | — | — | US | claimed |
| US-20140206657-A1 | BILE ACID ANALOG TGR5 AGONISTS | CITY OF HOPE (US) | 2014-07-24 | — | — | US | claimed |
| CN-101687120-B | Method for direct elution of reactive18F fluoride ions from anion exchange resins in an organic medium suitable for radiolabelling, without any evaporation step, by using strong organic bases | TRASIS S A | 2013-12-18 | — | — | CN | claimed |
| EP-2164590-B1 | METHOD FOR THE DIRECT ELUTION OF REACTIVE 18F FLUORIDE FROM AN ANION EXCHANGE RESIN IN AN ORGANIC MEDIUM SUITABLE FOR RADIOLABELLING WITHOUT ANY EVAPORATION STEP BY THE USE OF STRONG ORGANIC BASES | TRASIS S A (BE) | 2013-03-06 | — | — | EP | claimed |
| EP-2164590-A1 | METHOD FOR THE DIRECT ELUTION OF REACTIVE 18F FLUORIDE FROM AN ANION EXCHANGE RESIN IN AN ORGANIC MEDIUM SUITABLE FOR RADIOLABELLING WITHOUT ANY EVAPORATION STEP BY THE USE OF STRONG ORGANIC BASES | Trasis S.A. (BE) | 2010-03-24 | — | — | EP | claimed |
| WO-2009003251-A1 | METHOD FOR THE DIRECT ELUTION OF REACTIVE 18F FLUORIDE FROM AN ANION EXCHANGE RESIN IN AN ORGANIC MEDIUM SUITABLE FOR RADIOLABELLING WITHOUT ANY EVAPORATION STEP BY THE USE OF STRONG ORGANIC BASES | TRASIS S.A. (BE) | 2009-01-08 | — | — | WO | claimed |
| US-20260132310-A1 | HIGH STRENGTH URETHANE ACRYLATE HYBRID STRUCTURE ADHESIVES | ARKEMA FRANCE (FR) | 2026-05-14 | — | — | US | disclosed |
| US-20250188109-A1 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF | SLOAN KETTERING INSITUTE FOR CANCER RES (US) | 2025-06-12 | — | — | US | disclosed |
| US-12227535-B2 | Triterpene saponins, methods of synthesis and uses thereof | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH | 2025-02-18 | — | — | US | disclosed |
| WO-2024160806-A1 | HIGH STRENGTH URETHANE ACRYLATE HYBRID STRUCTURE ADHESIVES | ARKEMA FRANCE (FR) | 2024-08-08 | — | — | WO | disclosed |
| US-20070049620-A1 | Cyclic tertiary amine compound | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-0147012-B1 | METHOD AND APPARATUS FOR SEPARATING OXYGEN FROM A GASEOUS MIXTURE | AQUANAUTICS CORPORATION (a Delaware corporation) (US) | 1989-12-27 | — | — | EP | disclosed |
| EP-0147012-A2 | Method and apparatus for separating oxygen from a gaseous mixture | AQUANAUTICS CORPORATION (a Delaware corporation) (US) | 1985-07-03 | — | — | EP | disclosed |
| US-4475994-A | Method and apparatus for separating oxygen from a gaseous mixture | MAXDEM INCORPORATED (US) | 1984-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | MYD88, IL5, BRD4 | CYP3A4 680/4885TSHR 499/4885CYP2C19 658/4885 |
| US-20250188109-A1 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF | LSS, CYP51A1, TLR7 | CYP3A4 554/4885TSHR 3033/4885CYP2C19 1871/4885 |
| US-12227535-B2 | Triterpene saponins, methods of synthesis and uses thereof | LSS, CYP51A1, TLR7 | CYP3A4 617/4885TSHR 2842/4885CYP2C19 1902/4885 |
| US-20170233431-A1 | BILE ACID DERIVATIVES AND METHODS FOR SYNTHESIS AND USE | NR1H4, GPBAR1, SLC10A1 | CYP3A4 157/4885TSHR 669/4885CYP2C19 390/4885 |
| US-10246481-B2 | Bile acid derivatives and methods for synthesis and use | NR1H4, GPBAR1, SLC10A1 | CYP3A4 157/4885TSHR 669/4885CYP2C19 390/4885 |
| US-20260132310-A1 | HIGH STRENGTH URETHANE ACRYLATE HYBRID STRUCTURE ADHESIVES | HSPB1, PTK2, ICAM1 | CYP3A4 3653/4885TSHR 4670/4885CYP2C19 4420/4885 |
| US-20140206657-A1 | BILE ACID ANALOG TGR5 AGONISTS | GPBAR1, NR1H4, SLC10A1 | CYP3A4 505/4885TSHR 128/4885CYP2C19 1636/4885 |
| US-20180319836-A1 | BILE ACID DERIVATIVES AND METHODS FOR SYNTHESIS AND USE | NR1H4, GPBAR1, SLC10A1 | CYP3A4 157/4885TSHR 669/4885CYP2C19 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.